Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a regenerative and aesthetic medicine company whose news flow centers on its recombinant human collagen (rhCollagen) platform, 3D bioprinting activities and medical aesthetics programs. The company regularly issues updates on its rhCollagen-based BioInk products for 3D bioprinting of tissues and organs, tissue repair solutions and aesthetics-focused product candidates.
Investors following CLGN news can expect coverage of financial results reported via quarterly updates, including revenue trends from business collaborators, BioInk sales and tendon repair and wound healing products. CollPlant also reports on clinical and non-clinical milestones for its photocurable dermal and soft tissue filler program, regenerative breast implant development and its collaboration with AbbVie and Allergan on dermal and soft tissue fillers.
Another key news theme is scientific and research collaborations. CollPlant highlights studies such as the Technion – Israel Institute of Technology comparison of its Collink.3D bioink with Matrigel, and Mayo Clinic’s work on a fully humanized 3D bioprinted skin model using plant-derived rhCollagen. These items illustrate how the company’s materials are used in tissue engineering, disease modeling and non-animal alternatives for preclinical research.
Corporate and commercial updates are also frequent, including announcements about expansion of Vergenix STR tendon-repair product distribution in Europe, establishment of a North American logistics center for rhCollagen and BioInk distribution, and participation in industry conferences and investor events. For readers tracking developments in rhCollagen-based biomaterials, 3D bioprinting and aesthetic medicine, the CLGN news page provides an ongoing stream of company-generated information and regulatory disclosures.
CollPlant Biotechnologies (NASDAQ: CLGN) announced its fiscal year 2021 results, highlighting a significant GAAP revenue increase of 156%, reaching $15.6 million, primarily driven by a $14 million upfront payment from AbbVie. Gross profit surged 339% to $13.6 million. Operating expenses rose to $13.6 million, reflecting increased R&D and personnel costs. The company achieved a net income of $237,000, or $0.02 per share, contrasting with a net loss of $5.8 million in 2020. CollPlant plans to initiate a large animal study for its 3D bioprinted breast implant program in Q2 2022, targeting a market worth $2.8 billion.
CollPlant Biotechnologies and CELLINK announced a collaboration agreement on Feb. 16, 2022, to develop large-scale production of regenerative breast implants using CELLINK's 3D bioprinting technology. This collaboration targets a market worth $2.8 billion with approximately 2.2 million procedures conducted annually. CollPlant has produced prototypes of these implants, designed to naturally regenerate breast tissue. CELLINK's expertise in biofabrication is expected to assist in overcoming production challenges, aiming for commercialization to provide essential solutions for patients worldwide.
RION, a biotechnology company based in Rochester, Minnesota, has appointed Alisa Lask as Chief Commercial Officer. Lask brings extensive experience from leadership roles at major firms including Galderma and Allergan, aiming to commercially leverage RION's groundbreaking exosome therapeutics. The company currently has two active FDA registrations and focuses on innovative biologic platforms for regenerative medicine. Dr. Atta Behfar, RION's founder, expressed confidence in Lask's strategic vision to drive growth in both therapeutic and aesthetic sectors.
CollPlant Biotechnologies (Nasdaq: CLGN) recently shared a CEO letter detailing significant advancements in 2021. Key collaborations include partnerships with Allergan for dermal fillers and 3D Systems for breast reconstruction matrices. The company's revenues skyrocketed to $15.3 million, supported by a $14 million payment from AbbVie. Operational costs were managed, with R&D expenses at $5.4 million. CollPlant is enhancing its production capabilities and expanding its IP portfolio. The firm aims to lead in regenerative medicine and plans to launch more innovative products in the near future.
CollPlant announced the publication of an article in the Plastic and Reconstructive Surgery journal showcasing its photocurable dermal filler. The filler demonstrated enhanced lifting effects and improved tissue regeneration in preclinical models compared to standard options. Composed of recombinant human collagen, the filler aims to provide efficient contour corrections. The company continues to forge partnerships for product development, including collaborations with Allergan and 3D Systems for broader applications in regenerative medicine.
CollPlant Biotechnologies (NASDAQ: CLGN) reported its third-quarter financial results for 2021, revealing GAAP revenue of $140,000, down from $4.1 million in Q3 2020. The company recorded a net loss of $3.1 million, or $0.29 per share. Operating expenses increased to $3.1 million from $2.0 million year-over-year. However, for the nine-month period ending September 30, 2021, revenue surged 173% to $15.3 million, bolstered by a $14 million upfront payment from AbbVie. The recent launch of Collink.3D, a novel bioink for 3D bioprinting, positions CollPlant within a potential multi-billion dollar market.
CollPlant Biotechnologies (Nasdaq: CLGN) has launched Collink.3D, a recombinant human collagen-based BioInk solution for 3D bioprinting of tissues and organs. This product is designed to improve the bio-functionality and safety of bioprinted constructs, potentially transforming drug discovery and tissue testing. Collink.3D is fully human-derived, providing a scalable method to produce transplantable tissues. The company aims to establish partnerships with biopharma and academia to enhance product development. The introduction of this BioInk positions CollPlant in a lucrative market with extensive future applications.
CollPlant Biotechnologies (Nasdaq: CLGN) announced that Deputy CEO & CFO Eran Rotem will present at the Dawson James 6th Annual Small Cap Growth Conference on October 21, 2021, from 12:15-12:35 PM ET in Jupiter, Florida. The company specializes in regenerative medicine and 3D bioprinting technologies, focusing on tissue regeneration and organ manufacturing. Recently, CollPlant entered a global agreement with Allergan for dermal fillers and a co-development agreement with 3D Systems for a breast reconstruction product.
CollPlant Biotechnologies (Nasdaq: CLGN) announced that its recombinant human collagen (rhCollagen)-based bioink was successfully utilized by researchers at Israel's Technion Institute for creating a 3D bioprinted tissue with a vascular network. This innovation has the potential for transplantation without rejection. CEO Yehiel Tal emphasized the significant implications of this study for regenerative medicine. The research demonstrated that the implanted tissue supported cell survival and functionality post-transplantation. This milestone could lead to advances in lab-grown tissues for various medical applications.
CollPlant Biotechnologies (NASDAQ: CLGN) will present at the virtual Fall Harvest – Best Ideas from the Buy-Side conference from October 5-8, 2021. CEO Yehiel Tal will speak on October 5 at 8:30 AM ET. The presentation will be webcast live and available for replay. CollPlant specializes in regenerative medicine and has recently collaborated with Allergan for dermal fillers and with 3D Systems for bioprinted tissue matrices for breast reconstruction. The company aims to innovate in medical aesthetics and tissue regeneration.